Interpace Biosciences, Inc. (IDXG)
OTCMKTS · Delayed Price · Currency is USD
1.545
+0.085 (5.82%)
Jul 27, 2026, 1:31 PM EST

Interpace Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
36.2538.7346.9340.0431.8433.12
Revenue Growth
-24.90%-17.47%17.21%25.75%-3.86%2.22%
Gross Profit
22.6624.1329.9325.0618.2318.8
Operating Income
4.084.788.113.96-3.84-5.76
Net Income
23.6524.586.241.95-21.96-14.94
Earnings Per Share
0.860.891.390.45-5.18-3.61
EPS Growth
-19.01%-36.52%210.60%---

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
2.652.511.463.54.832.67
Total Debt
1.081.185.8611.1916.0910.72
Net Cash (Debt)
1.571.32-4.4-7.69-11.26-8.05
Net Cash Growth
------
Net Cash Per Share
0.060.05-0.28-1.76-2.66-1.95

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
4.885.834.653.79-7.69-8.72
Capital Expenditures
-0.5-0.36-0.88-0.47-0.32-0.35
Free Cash Flow
4.385.483.773.32-8.01-9.07
Free Cash Flow Growth
-13.93%45.23%13.59%---

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
62.53%62.31%63.77%62.58%57.26%56.78%
Operating Margin
11.25%12.35%17.28%9.90%-12.06%-17.41%
Pretax Margin
8.65%9.74%14.81%5.70%-18.33%-23.38%
Profit Margin
65.25%63.45%13.29%4.88%-68.97%-45.12%
FCF Margin
12.09%14.14%8.03%8.29%-25.17%-27.40%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
1.780.221.902.40--
Forward PE
-111.43111.43111.43111.43111.43
P/FCF Ratio
9.761.003.151.41--
PS Ratio
1.180.140.250.120.140.94